A Novel Mode of Gleevec Binding Is Revealed by the Structure of Spleen Tyrosine Kinase*
暂无分享,去创建一个
Stephen K Burley | Shane Atwell | S. Burley | S. Atwell | K. Rajashankar | K. Froning | V. Nienaber | S. Buchanan | Xia Gao | K. Post | B. Noland | M. Russell | J. Badger | M. Buchanan | I. Feil | J. Hendle | A. Ramos | Jason M Adams | B. Leon | Marijane Russell | Sean G Buchanan | Karen J Froning | Barbara C Leon | Vicki L Nienaber | K. Keegan | Hans-Joachim Müller-Dieckmann | John Badger | Michelle D Buchanan | Ingeborg K Feil | Xia Gao | Jörg Hendle | Kevin Keegan | Hans J Müller-Dieckmann | Brian W Noland | Kai Post | K R Rajashankar | Aurora Ramos
[1] Eugene C. Petrella,et al. The Three-dimensional Structure of the ZAP-70 Kinase Domain in Complex with Staurosporine , 2004, Journal of Biological Chemistry.
[2] J. D. Di Santo,et al. Tyrosine kinase SYK: essential functions for immunoreceptor signalling. , 2000, Immunology today.
[3] S. Hubbard. Crystal structure of the activated insulin receptor tyrosine kinase in complex with peptide substrate and ATP analog , 1997, The EMBO journal.
[4] M. Shibuya,et al. Epidermal growth factor-receptor mutant lacking the autophosphorylation sites induces phosphorylation of Shc protein and Shc-Grb2/ASH association and retains mitogenic activity. , 1994, Proceedings of the National Academy of Sciences of the United States of America.
[5] A. Veillette,et al. Differential Intrinsic Enzymatic Activity of Syk and Zap-70 Protein-tyrosine Kinases* , 1996, The Journal of Biological Chemistry.
[6] D E McRee,et al. XtalView/Xfit--A versatile program for manipulating atomic coordinates and electron density. , 1999, Journal of structural biology.
[7] John Kuriyan,et al. Crystal structures of the kinase domain of c-Abl in complex with the small molecule inhibitors PD173955 and imatinib (STI-571). , 2001, Cancer research.
[8] P. Seeburg,et al. Structural mechanism for STI-571 inhibition of abelson tyrosine kinase. , 2000, Science.
[9] Hsien-yu Wang,et al. Gsα Repression of Adipogenesis via Syk* , 1999, The Journal of Biological Chemistry.
[10] L. Johnson,et al. Protein kinase inhibition by staurosporine revealed in details of the molecular interaction with CDK2 , 1997, Nature Structural Biology.
[11] M. Shibuya,et al. A highly conserved tyrosine residue at codon 845 within the kinase domain is not required for the transforming activity of human epidermal growth factor receptor. , 1992, Biochemical and biophysical research communications.
[12] M. Turner,et al. Critical role for the tyrosine kinase Syk in signalling through the high affinity IgE receptor of mast cells. , 1996, Oncogene.
[13] J. Kuriyan,et al. The Conformational Plasticity of Protein Kinases , 2002, Cell.
[14] L. Toledo,et al. Structural analysis of the lymphocyte-specific kinase Lck in complex with non-selective and Src family selective kinase inhibitors. , 2000, Structure.
[15] S. Hubbard,et al. Structures of the tyrosine kinase domain of fibroblast growth factor receptor in complex with inhibitors. , 1997, Science.
[16] Collaborative Computational,et al. The CCP4 suite: programs for protein crystallography. , 1994, Acta crystallographica. Section D, Biological crystallography.
[17] L. Tong,et al. Inhibition of p38 MAP kinase by utilizing a novel allosteric binding site , 2002, Nature Structural Biology.
[18] K. Sada,et al. Role of the Syk autophosphorylation site and SH2 domains in B cell antigen receptor signaling , 1995, The Journal of experimental medicine.
[19] T. Hunter,et al. The eukaryotic protein kinase superfamily: kinase (catalytic) domain structure and classification 1 , 1995, FASEB journal : official publication of the Federation of American Societies for Experimental Biology.
[20] Teruaki Kimura,et al. Mutations in the activation loop tyrosines of protein tyrosine kinase Syk abrogate intracellular signaling but not kinase activity. , 1998, Journal of immunology.
[21] S. Hubbard,et al. Protein tyrosine kinase structure and function. , 2000, Annual review of biochemistry.
[22] Jürg Zimmermann,et al. Potent and selective inhibitors of the Abl-kinase: phenylamino-pyrimidine (PAP) derivatives , 1997 .
[23] J. Zhang,et al. Transfection of Syk protein tyrosine kinase reconstitutes high affinity IgE receptor-mediated degranulation in a Syk-negative variant of rat basophilic leukemia RBL-2H3 cells , 1996, The Journal of experimental medicine.
[24] G. Superti-Furga,et al. Structural Basis for the Autoinhibition of c-Abl Tyrosine Kinase , 2003, Cell.
[25] J. Kuriyan,et al. Multiple BCR-ABL kinase domain mutations confer polyclonal resistance to the tyrosine kinase inhibitor imatinib (STI571) in chronic phase and blast crisis chronic myeloid leukemia. , 2002, Cancer cell.
[26] D. Barford,et al. Mechanism of Activation of the RAF-ERK Signaling Pathway by Oncogenic Mutations of B-RAF , 2004, Cell.
[27] S. Latour,et al. Proximal protein tyrosine kinases in immunoreceptor signaling. , 2001, Current opinion in immunology.
[28] M. Sliwkowski,et al. Structure of the Epidermal Growth Factor Receptor Kinase Domain Alone and in Complex with a 4-Anilinoquinazoline Inhibitor* , 2002, The Journal of Biological Chemistry.
[29] J. Kuriyan,et al. Crystal structure of Hck in complex with a Src family-selective tyrosine kinase inhibitor. , 1999, Molecular cell.
[30] John Badger,et al. Reliable quality-control methods for protein crystal structures. , 2002, Acta crystallographica. Section D, Biological crystallography.
[31] Hiroto Yamaguchi,et al. Structural basis for activation of human lymphocyte kinase Lck upon tyrosine phosphorylation , 1996, Nature.
[32] S. Hubbard,et al. Crystal structure of the tyrosine kinase domain of the human insulin receptor , 1994, Nature.
[33] T. Mustelin,et al. Role of Tyr518 and Tyr519 in the regulation of catalytic activity and substrate phosphorylation by Syk protein-tyrosine kinase. , 1997, European journal of biochemistry.
[34] W. Hofmann,et al. Mechanisms of Resistance to STI571 (Imatinib) in Philadelphia-chromosome Positive Acute Lymphoblastic Leukemia , 2004, Leukemia & lymphoma.
[35] S. Knapp,et al. Crystal structure of the tyrosine kinase domain of the hepatocyte growth factor receptor c-Met and its complex with the microbial alkaloid K-252a , 2003, Proceedings of the National Academy of Sciences of the United States of America.
[36] A. Weiss,et al. The Syk family of protein tyrosine kinases in T‐cell activation and development , 1998, Immunological reviews.
[37] Randall L. Kincaid,et al. Phosphorylation of Syk Activation Loop Tyrosines Is Essential for Syk Function , 2000, The Journal of Biological Chemistry.